CA3115038A1 - Egfr inhibitors for treating keratodermas - Google Patents

Egfr inhibitors for treating keratodermas Download PDF

Info

Publication number
CA3115038A1
CA3115038A1 CA3115038A CA3115038A CA3115038A1 CA 3115038 A1 CA3115038 A1 CA 3115038A1 CA 3115038 A CA3115038 A CA 3115038A CA 3115038 A CA3115038 A CA 3115038A CA 3115038 A1 CA3115038 A1 CA 3115038A1
Authority
CA
Canada
Prior art keywords
syndrome
keratoderma
egfr
patient
palmoplantar keratoderma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3115038A
Other languages
English (en)
French (fr)
Inventor
Christine BODEMER
Celine Greco
Claude Boucheix
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris Sud
Fondation Imagine
Universite Paris Cite
Original Assignee
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris Sud
Universite de Paris
Fondation Imagine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assistance Publique Hopitaux de Paris APHP, Institut National de la Sante et de la Recherche Medicale INSERM, Universite Paris Sud, Universite de Paris, Fondation Imagine filed Critical Assistance Publique Hopitaux de Paris APHP
Publication of CA3115038A1 publication Critical patent/CA3115038A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
CA3115038A 2018-10-04 2019-10-03 Egfr inhibitors for treating keratodermas Pending CA3115038A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18306306 2018-10-04
EP18306306.4 2018-10-04
PCT/EP2019/076803 WO2020070239A1 (en) 2018-10-04 2019-10-03 Egfr inhibitors for treating keratodermas

Publications (1)

Publication Number Publication Date
CA3115038A1 true CA3115038A1 (en) 2020-04-09

Family

ID=63857839

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3115038A Pending CA3115038A1 (en) 2018-10-04 2019-10-03 Egfr inhibitors for treating keratodermas

Country Status (9)

Country Link
US (1) US12491186B2 (https=)
EP (1) EP3860608A1 (https=)
JP (2) JP2022512584A (https=)
CN (1) CN113194954A (https=)
AU (1) AU2019352741A1 (https=)
BR (1) BR112021006407A8 (https=)
CA (1) CA3115038A1 (https=)
IL (1) IL282041A (https=)
WO (1) WO2020070239A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4003299A4 (en) * 2019-07-24 2023-08-23 Sol-Gel Technologies Ltd. Treatment of skin disorders with topical tapinarof-egfr inhibitor compositions
KR20220097429A (ko) * 2019-11-06 2022-07-07 솔-겔 테크놀로지스 리미티드 손발바닥각피증 치료 방법
EP4132532A1 (en) 2020-04-07 2023-02-15 Laboratoires C.T.R.S. Topical use of erlotinib for treating keratodermas in children
KR102536315B1 (ko) * 2020-09-11 2023-05-25 아주대학교산학협력단 네라티닙을 유효성분으로 포함하는 퇴행성 관절염 예방 또는 치료용 조성물
CN120309699B (zh) * 2025-04-18 2025-11-21 中国医学科学院基础医学研究所 稀释诱导相分离多肽及其应用

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
NZ226171A (en) 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
SG64322A1 (en) 1991-05-10 1999-04-27 Rhone Poulenc Rorer Int Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9215665D0 (en) 1992-07-23 1992-09-09 British Bio Technology Compounds
KR100312097B1 (ko) 1993-08-09 2002-11-13 가네보 가부시키가이샤 아실페닐글리신 유도체 및 그 화합물을 유효성분으로하는,콜라게나제활성증진에기인한질환의예방및치료제
JPH09503201A (ja) 1993-08-23 1997-03-31 イミュネックス・コーポレーション Ｔｎｆ−アルファ分泌の阻害剤
WO1995009847A1 (en) 1993-10-01 1995-04-13 Ciba-Geigy Ag Pyrimidineamine derivatives and processes for the preparation thereof
US5656643A (en) 1993-11-08 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
DE59500788D1 (de) 1994-05-03 1997-11-20 Ciba Geigy Ag Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
CA2214086C (en) 1995-04-03 2008-07-29 Novartis Ag Pyrazole derivatives and processes for the preparation thereof
JP3814696B2 (ja) 1995-04-17 2006-08-30 住友精化株式会社 芳香族またはヘテロ芳香族スルホニルハライド類の製造方法
US5691381A (en) 1995-04-18 1997-11-25 The Dupont Merck Pharmaceutical Company Hydroxamic and carbocyclic acids as metalloprotease inhibitors
WO1996033968A1 (en) 1995-04-25 1996-10-31 Fuji Yakuhin Kogyo Kabushiki Kaisha Highly water-soluble metalloproteinase inhibitor
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5650415A (en) 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds
GB9513331D0 (en) 1995-06-30 1995-09-06 British Biotech Pharm Matrix metalloproteinase inhibitors
SI9620103A (sl) 1995-07-06 1998-10-31 Novartis Ag Pirolopirimidini in postopki za njihovo pripravo
DK9500262U4 (da) 1995-07-07 1996-10-07 Bonus Energy As Bundramme til vindmøllehus samt vindmølle omfattende samme
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
US6281352B1 (en) 1995-11-14 2001-08-28 Dupont Pharmaceuticals Company Macrocyclic compounds as metalloprotease inhibitors
CA2237524A1 (en) 1995-11-14 1997-05-22 Du Pont Pharmaceuticals Company Novel macrocyclic compounds as metalloprotease inhibitors
US5665777A (en) 1995-11-14 1997-09-09 Abbott Laboratories Biphenyl hydroxamate inhibitors of matrix metalloproteinases
GB9523637D0 (en) 1995-11-18 1996-01-17 British Biotech Pharm Synthesis of carboxylic acid derivatives
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
ATE205184T1 (de) 1995-11-23 2001-09-15 British Biotech Pharm Metalloproteinase inhibitoren
ES2233275T3 (es) 1995-12-08 2005-06-16 Agouron Pharmaceuticals, Inc. Intermediarios que sirven para la preparacion de inhibidores de metaloproteinasas.
PT871439E (pt) 1996-01-02 2004-08-31 Aventis Pharma Inc Compostos do acido hidroxamico substituidos (arilo heteroarilo arilmetilo ou heteroarilmetilo)
AU1441497A (en) 1996-01-23 1997-08-20 Novartis Ag Pyrrolopyrimidines and processes for their preparation
JP3406763B2 (ja) 1996-01-30 2003-05-12 東レ・ダウコーニング・シリコーン株式会社 シリコーンゴム組成物
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9603097D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
DE19629652A1 (de) 1996-03-06 1998-01-29 Thomae Gmbh Dr K 4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE19608588A1 (de) 1996-03-06 1997-09-11 Thomae Gmbh Dr K Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
WO1997034895A1 (de) 1996-03-15 1997-09-25 Novartis Ag NEUE N-7 HETEROCYCLYL-PYRROLO[2,3-d]PYRIMIDINE UND IHRE VERWENDUNG
EA001595B1 (ru) 1996-04-12 2001-06-25 Варнер-Ламберт Компани Необратимые ингибиторы тирозинкиназ
GB9607729D0 (en) 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
WO1997042168A1 (en) 1996-05-06 1997-11-13 Zeneca Limited Thio derivatives of hydroxamic acids
GB9609795D0 (en) 1996-05-10 1996-07-17 Smithkline Beecham Plc Novel compounds
GB9609794D0 (en) 1996-05-10 1996-07-17 Smithkline Beecham Plc Novel compounds
CA2258548C (en) 1996-06-24 2005-07-26 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
GB9613547D0 (en) 1996-06-27 1996-08-28 Pharmacia Spa Matrix metalloproteinase inhibitors
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
EA199900021A1 (ru) 1996-07-13 1999-08-26 Глаксо, Груп Лимитед Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы
AR007857A1 (es) 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
GB9715962D0 (en) 1996-08-23 1997-10-01 Zeneca Ltd Sulfonamides
WO1998007726A1 (en) 1996-08-23 1998-02-26 Novartis Ag Substituted pyrrolopyrimidines and processes for their preparation
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
AU4779897A (en) 1996-10-02 1998-04-24 Novartis Ag Fused pyrazole derivatives and processes for their preparation
US6251911B1 (en) 1996-10-02 2001-06-26 Novartis Ag Pyrimidine derivatives and processes for the preparation thereof
JP2001503037A (ja) 1996-10-16 2001-03-06 アメリカン・サイアナミド・カンパニー マトリクス金属プロテナイーゼおよびｔａｃｅに対する阻害薬としてのオルト―スルホンアミドヘテロアリールヒドロキサム酸の製造および使用
AU736134B2 (en) 1996-10-16 2001-07-26 Wyeth Holdings Corporation Beta-sulfonamido hydroxamic acids as matrix metalloproteinase and tace inhibitors
HUP0000641A3 (en) 1996-10-16 2001-02-28 American Cyanamid Company Madi Ortho-sulfonamido aryl hydroxamic acid derivatives, their use, as matrix metalloproteinase and tace inhibitors and pharmaceutical compositions containing them
AU743901B2 (en) 1996-10-16 2002-02-07 Wyeth Holdings Corporation Ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloprote inase and tace inhibitors
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
GB9621757D0 (en) 1996-10-18 1996-12-11 Ciba Geigy Ag Phenyl-substituted bicyclic heterocyclyl derivatives and their use
ZA9820B (en) 1997-01-07 1998-07-02 Abbott Lab Macrocyclic inhibitors of matrix metalloproteinases and tnf x secretion
ZA9818B (en) 1997-01-07 1998-07-02 Abbott Lab C-terminal ketone inhibitors of matrix metalloproteinases and tnf alpha secretion
PL334846A1 (en) 1997-01-23 2000-03-27 Hoffmann La Roche Sulphamidic inhibitors of metaloproteases
WO1998033798A2 (en) 1997-02-05 1998-08-06 Warner Lambert Company Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation
PL335378A1 (en) 1997-02-26 2000-04-25 Glaxo Group Ltd Derivatives of inverse hydroxamates as metaloprotease inhibitors
YU40999A (sh) 1997-02-27 2002-06-19 American Cyanamid Company N-hidroksi-2-(alkil,aril ili heteroaril sulfanil,sulfinil ili sulfonil)-3-supstituisani alkil,aril ili heteroarilamidi, kao inhibitori za matrične metaloproteinaze
US7115632B1 (en) 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
WO1998039326A1 (en) 1997-03-04 1998-09-11 Monsanto Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
WO1998043963A1 (en) 1997-04-01 1998-10-08 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
WO1999002510A1 (en) 1997-07-10 1999-01-21 Pharmacia & Upjohn S.P.A. Matrix metalloproteinase inhibitors
IT1296305B1 (it) 1997-07-17 1999-06-25 Polifarma Spa Inibitori di metalloproteinasi loro uso terapeutico e procedimento per la produzione del composto di partenza nella loro
EP1003751A1 (en) 1997-08-04 2000-05-31 Amgen Inc. Hydroxamic acid substituted fused heterocyclic metalloproteinase inhibitors
AU8689298A (en) 1997-08-05 1999-03-01 Sugen, Inc. Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
PT1015095E (pt) 1997-08-25 2001-10-30 Hydac Filtertechnik Gmbh Elemento de filtracao com revestimento de filtracao constituido por material sintetico
PT1021413E (pt) 1997-10-06 2003-10-31 Wyeth Corp A preparacao e utilizacao de acidos orto-sulfonamido heterociclicos biciclicos hidroxamicos como inibidores de metaloproteinases de matriz e de tace
US6750228B1 (en) 1997-11-14 2004-06-15 Pharmacia Corporation Aromatic sulfone hydroxamic acid metalloprotease inhibitor
WO1999031052A1 (fr) 1997-12-12 1999-06-24 Fuji Yakuhin Kogyo Kabushiki Kaisha Nouveaux inhibiteurs de metalloproteinases
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
EP1051407A1 (en) 1998-01-27 2000-11-15 American Cyanamid Company 2,3,4,5-tetrahydro-1h-[1,4]-benzodiazepine-3-hydroxamic acids as matrix metalloproteinase inhibitors
WO1999042436A1 (en) 1998-02-19 1999-08-26 American Cyanamid Company N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted-alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
CN1301265A (zh) 1998-05-14 2001-06-27 杜邦药品公司 新的用作金属蛋白酶抑制剂的取代的芳基异羟肟酸
WO1999061412A1 (en) 1998-05-22 1999-12-02 Welfide Corporation Hydroxamic acid derivatives and medicinal utilization thereof
GB9919776D0 (en) 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
US6552223B1 (en) 1998-08-31 2003-04-22 Astrazeneca Ab N-hydroxacylamino compounds, process for their preparation and pharmaceutical compositions containing them
AU765729B2 (en) 1998-12-11 2003-09-25 F. Hoffmann-La Roche Ag Cyclic hydrazine derivatives as TNF-alpha inhibitors
AR022422A1 (es) 1999-01-27 2002-09-04 American Cyanamid Co Inhibidores de tace acetilenicos de acido hidroxamico de heteroarilfulfonamida y amida del acido fosfinico
AR035313A1 (es) 1999-01-27 2004-05-12 Wyeth Corp Inhibidores de tace acetilenicos de acido hidroxamico de sulfonamida a base de alfa-aminoacidos, composiciones farmaceuticas y el uso de los mismos para la manufactura de medicamentos.
AU766192B2 (en) 1999-01-27 2003-10-09 Wyeth Holdings Corporation Acetylenic sulfonamide thiol tace inhibitors
AR035478A1 (es) 1999-01-27 2004-06-02 Wyeth Corp Acido amida-hidroxamico, acido acetilenico, beta-sulfonamido y fosfinico como inhibidores de la tace, uso de los mismos para la manufactura de un medicamento y composicion farmaceutica que los contiene
EP1144369B1 (en) 1999-01-27 2004-07-21 Wyeth Holdings Corporation Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
AR022424A1 (es) 1999-01-27 2002-09-04 American Cyanamid Co Compuestos derivados de acidos ortosulfonamido acetilenico e hidroxamico biciclico heteroarilo amido de acido fosfinico como inhibidores tace, composicionfarmaceutica que los comprende y el uso de los mismos para la manufactura de un medicamento
AR022423A1 (es) 1999-01-27 2002-09-04 American Cyanamid Co Compuestos derivados de acidos 2,3,4,5-tetrahidro-1h-[1,4]benzodiazepina-3-hidroxamicos, composicion farmaceutica que los comprenden, y el uso de losmismos para la manufactura de un medicamento
AR035311A1 (es) 1999-01-27 2004-05-12 Wyeth Corp Derivados de acido hidroxamico que contienen alquinilo, como inhibidores de las metalloproteinasas de matriz y de la tace, composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento
US6358980B1 (en) 1999-01-27 2002-03-19 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
AU2320500A (en) 1999-02-02 2000-08-25 Shionogi & Co., Ltd. Sulfonamide derivatives having cyclic structures
HRP20010660A2 (en) 1999-02-08 2005-02-28 G.D. Searle & Co Sulfamato hydroxamic acid metalloprotease inhibitor
CA2367963A1 (en) 1999-03-22 2000-09-28 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives
EP1165546A2 (en) 1999-04-02 2002-01-02 Du Pont Pharmaceuticals Company Novel lactam inhibitors of matrix metalloproteinases, tnf-alpha, and aggrecanase
GB9911073D0 (en) 1999-05-12 1999-07-14 Darwin Discovery Ltd Hydroxamic and carboxylic acid derivatives
GB9911075D0 (en) 1999-05-12 1999-07-14 Darwin Discovery Ltd HYdroxamic and carboxylic acid derivatives
GB9911071D0 (en) 1999-05-12 1999-07-14 Darwin Discovery Ltd Hydroxamic and carboxylic acid derivatives
AU781339B2 (en) 1999-05-12 2005-05-19 G.D. Searle & Co. Hydroxamic acid derivatives as matrix metalloprotease inhibitors
AU4614000A (en) 1999-05-17 2000-12-05 Daiichi Fine Chemical Co., Ltd. Novel hydroxamic acid derivatives
US6583299B1 (en) 1999-05-20 2003-06-24 G.D. Searle & Co. α-amino-β-sulfonyl hydroxamic acid compounds
JP2003501414A (ja) 1999-06-04 2003-01-14 アストラゼネカ・アクチエボラーグ メタロプロテイナーゼの阻害剤
CA2378332A1 (en) 1999-08-18 2001-02-22 Christopher Alan Conrad Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors
GB9922825D0 (en) 1999-09-25 1999-11-24 Smithkline Beecham Biolog Medical use
US6632667B1 (en) 1999-10-28 2003-10-14 Isis Pharmaceuticals, Inc. Modulation of L-selectin shedding via inhibition of tumor necrosis factor-α converting enzyme (TACE)
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
GB9929979D0 (en) 1999-12-17 2000-02-09 Darwin Discovery Ltd Hydroxamic acid derivatives
EP1252143A1 (en) 2000-01-27 2002-10-30 American Cyanamid Company Method for preparing alpha-sulfonyl hydroxamic acid derivatives
US6989139B2 (en) 2000-02-15 2006-01-24 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
KR20020079882A (ko) 2000-02-21 2002-10-19 아스트라제네카 아베 아릴피페라진 및 아릴피페리딘 및 금속단백질분해효소억제제로서의 그의 용도
JP2003524007A (ja) 2000-02-21 2003-08-12 アストラゼネカ・アクチエボラーグ アリールピペラジン類およびそれらのメタロプロテイナーゼ阻害剤（ｍｍｐ）としての使用
WO2001062742A1 (en) 2000-02-21 2001-08-30 Astrazeneca Ab Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
AR027943A1 (es) 2000-02-25 2003-04-16 Wyeth Corp Acidos orto-sulfonamido aril hidroxamicos como inhibidores de metaloproteinasa de matriz y preparacion de los mismos
IL151552A0 (en) 2000-03-17 2003-04-10 Bristol Myers Squibb Pharma Co Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
DE60102137T2 (de) 2000-03-17 2004-10-21 Bristol Myers Squibb Pharma Co Beta-aminsäure-derivate zur verwendung als matrix-metalloproteasen- und tna-alpha-inhibitoren
EP1282614B1 (en) 2000-05-15 2003-11-12 Darwin Discovery Limited Hydroxamic acid derivatives
EP1286994A1 (en) 2000-05-15 2003-03-05 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
US6620823B2 (en) 2000-07-11 2003-09-16 Bristol-Myers Squibb Pharme Company Lactam metalloprotease inhibitors
GB0017435D0 (en) 2000-07-14 2000-08-30 Pharmacia & Upjohn Spa 3-arylsulfonyl-2-hydroxy-2-methylpropanoic acid derivatives
US20060084691A1 (en) * 2004-10-18 2006-04-20 Bilal Piperdi Combined treatment with bortezomib and an epidermal growth factor receptor kinase inhibitor
WO2009091889A1 (en) * 2008-01-18 2009-07-23 Georgetown University Treatment of skin disorders with egfr inhibitors
WO2012005229A1 (ja) 2010-07-08 2012-01-12 科研製薬株式会社 Ｎ－ヒドロキシホルムアミド誘導体およびそれを含有する医薬

Also Published As

Publication number Publication date
CN113194954A (zh) 2021-07-30
JP2025004113A (ja) 2025-01-14
AU2019352741A1 (en) 2021-05-06
US20210393632A1 (en) 2021-12-23
BR112021006407A2 (pt) 2021-07-27
US12491186B2 (en) 2025-12-09
WO2020070239A1 (en) 2020-04-09
JP2022512584A (ja) 2022-02-07
IL282041A (en) 2021-05-31
BR112021006407A8 (pt) 2022-12-06
EP3860608A1 (en) 2021-08-11

Similar Documents

Publication Publication Date Title
US12491186B2 (en) EGFR inhibitors for treating keratodermas
Thakur et al. Vitiligo: translational research and effective therapeutic strategies
KR20040102117A (ko) 건선 및 기타 피부 질병의 치료에서 시클로파민의 용도
KR20150036351A (ko) 염증성 피부 질환의 치료
WO2009114745A1 (en) Formulations of vitamin k analogs for topical use
JPH11502513A (ja) 糖尿病性ニューロパシーの処置方法
EP2958549A1 (en) Combinations of indigo naturalis and berberine and uses thereof
JP6130846B2 (ja) 皮膚の色素沈着の誘導並びに皮膚の色素異常及び白斑の治療のためのｎｇｆを含有する局所用製剤
US10201535B2 (en) Pharmaceutical compositions comprising 7-(1H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
WO2017129108A1 (zh) 一种用于治疗皮肤病的硅凝胶
BR112015021668B1 (pt) Agonista de receptor ss2-adrenérgico para melhorar a correspondência de cor de pele de cicatriz
JP2025032101A (ja) 皮膚状態を治療するために抗ｖｅｇｆ化合物を適用するためおよびこのような化合物を使用するためのシステム、デバイスおよび方法
US20210161816A1 (en) Methods and compositions for treating skin afflictions
EP3654984A1 (en) Topical treatment for preventing and mitigating skin cytotoxicity due to therapy with tyrosine kinase inhibitors
US20220265670A1 (en) Composition and use thereof for the treatment of cutaneous mastocytosis
RU2722396C2 (ru) Способ лечения пальмарно-плантарной эритродизестезии
US20160303085A1 (en) Pharmaceutical composition comprising a ryanodine receptor antagonist for facilitating wound healing
KR20190017801A (ko) 티몰롤을 포함하는 조성물 및 국소 투여에 의한 주사의 치료에 있어서의 이들의 용도
Singh et al. Use of Nanotechnology in Pain Management
KR20250113980A (ko) 튜불린 저해제를 포함하는 피부 질환 예방 또는 치료용 조성물
WO2014078868A1 (en) Methods of treatment of keratinocyte-derived lesions
JP2024513192A (ja) 色素沈着過剰障害を処置するための方法及び組成物
US20060088556A1 (en) Topical formulation and use of buspirone
HK40015081A (en) Topical phenytoin for use in the treatment of peripheral neuropathic pain

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231204

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240925

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240925

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240925

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241203

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250327

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250404

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250716

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250716

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250923

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250923

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251027

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260220

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260223

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260223

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260223